Salt Lake City, UT — April 20, 2026 — The L. S. Peery, M.D. Orthopaedic Innovation Center at the Department of Orthopaedics, Spencer Fox Eccles School of Medicine, University of Utah, today announced FDA 510(k) clearance of the CoAptix™ S 7.5mm System, a dynamic compression, cannulated, headed and headless bone screw system in lengths ranging from 45mm to 180mm. The bone screws are engineered to provide continuous dynamic compression to a bony repair construct in the presence of up to 4mm of resorption at the bone healing interface.
University Of Utah Orthopaedic Innovation Center Announces FDA Clearance of Breakthrough Dynamic Compression Implant System
2 min read Premium comments
Breaking NewsOTWPRCoAptix™ S 7.5mm SystemUniversity of UtahFDA 510(k) clearance
The CoAptix™ S 7.5mm Systemis part of the CoAptix™ platform technology, a Dynamic Compression Implant System that includes Bone Screws, Intramedullary Fixation Devices, and Hybrid Devices designed to transform fracture fixation, joint fusion, and osteotomy stabilization by potentially reducing the incidence rate of non-unions. Development of the smaller CoAptix™ S 3.5mm, 4.5mm, 5.5mm, and 6.5mm System, also a cannulated, headed and headless bone screw system, is currently underway.
Unlike traditional static implants, the CoAptix™ technology delivers continuous dynamic compression, a proven biomechanical principle that has already revolutionized bone staple technology. Just as dynamic compression bone staples made from nitinol have replaced static staples made from stainless steel, dynamic compression screws and dynamic compression intramedullary devices are poised to become the new standard in orthopedic fixation.
The Dynamic Compression Implant System is backed by a robust intellectual property portfolio:
- Six issued U.S. patents with additional U.S. and international applications pending
- A strong patent estate expected to form a dominant position in the dynamic compression implant space
“This technology represents an important evolution in orthopedic fixation,” said Wade Fallin, Executive Director of the LS Peery, MD Orthopaedic Innovation Center and Dr. Louis S. and Janet B. Peery Presidential Research Professor. “Dynamic compression has demonstrated clear biomechanical and clinical advantages. With our patented platform, we believe we are on the cusp of transforming orthopedic surgery worldwide.”“This platform reflects the University’s strength in translating orthopedic innovation into real-world solutions,” said Jamie Dwyer, Interim Chief Innovation Officer at the University of Utah’s Technology Licensing Office. “We’re poised to work with medical device companies and strategic partners to accelerate commercialization and expand access to these transformative technologies.”
The Orthopaedic Innovation Center is actively engaging with medical device companies and strategic partners interested in licensing or acquiring rights to the Dynamic Compression Implant System.
Contact:
About the Orthopaedic Innovation Center (“OIC”)
The OIC is dedicated to advancing musculoskeletal health through novel medical device technologies, translational research, and partnerships with industry leaders. Located within the Department of Orthopaedics, Specer Fox Eccles School of Medicine, University of Utah, and in collaboration with the Technology Licensing Office, the OIC has a proven track record of innovation and successful technology transfer. For more information regarding the OIC, contact Wade Fallin at wade.fallin@hsc.utah.edu.
About the Technology Licensing Office
The University of Utah Technology Licensing Office (TLO) is dedicated to fostering innovation and creating value through effective technology transfer. As a leader in managing intellectual property, the TLO empowers researchers and inventors by providing the resources and support needed to transform groundbreaking ideas into real-world solutions. By facilitating the journey from discovery to commercialization, the TLO plays a critical role in driving economic growth and societal impact.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.